Ideaya Biosciences promotes chief scientific officer to president of R&D

Ideaya Biosciences (NASDAQ: IDYA) announced the promotion of Dr. Michael White from Chief Scientific Officer to President, Research and Development, effective September 28, 2026.

Dr. White has served as Chief Scientific Officer at Ideaya since 2021. Before joining Ideaya, he was Chief Scientific Officer and Head of Tumor Biology at Pfizer, where he led oncology small-molecule research and development efforts. Prior to Pfizer, Dr. White held a position as Professor of Cell Biology at UT Southwestern, where he also served as founding Director of the Cancer Intervention and Prevention Discovery Program during a career spanning more than two decades.

In 2015, Dr. White received the inaugural Outstanding Investigator's Award from the National Cancer Institute. He has authored more than 150 publications with over 30,000 citations. He holds a Ph.D. in Biology from the University of North Carolina at Chapel Hill and completed postdoctoral research at Cold Spring Harbor Laboratories in New York.

Yujiro S. Hata, President and Chief Executive Officer of Ideaya Biosciences, said in a statement that Dr. White "has demonstrated exceptional leadership and has been a key driver in advancing IDEAYA's mission" during his five-year tenure as Chief Scientific Officer.

Ideaya is a precision medicine oncology company focused on the development of targeted therapeutics for solid tumor indications, including uveal melanoma, pancreatic cancer, small cell lung cancer, non-small cell lung cancer, colorectal cancer, and breast cancer, according to the company's press release.

You May Also Be Interested In

• LKQ names Salvatore Abbate as CEO, effective December 15
• Zymeworks ZW191 shows 64.5% response rate in ovarian cancer trial
• CRH closes $8.5B acquisition of Arcosa